UPDATE : Thursday, August 22, 2019
상단여백
‘Drug firm’s pick of doctor to attend conference overseas illegal’
Pharmaceutical companies’ support for physicians to attend academic confere...
by Kim Yun-mi  |  2019-08-22 15:45
라인
Rivalry among PARP inhibitors intense in ovarian cancer treatment
Pharmaceutical firms’ war using PARP inhibitors, a group of pharmacological...
by Kim Yun-mi  |  2019-08-19 14:00
라인
Diabetes drug Jardiance pressures heart failure treatment Entresto
Novartis’ new heart failure treatment Entresto (ingredient: sacubitril/vals...
by Kim Yun-mi  |  2019-08-09 15:44
라인
Lilly’s anticancer combo drug nears getting insurance benefit
Eli Lilly said its anticancer drug Verzenio showed an improvement in overal...
by Kim Yun-mi  |  2019-08-07 15:44
라인
Japanese firms fear boycott may hurt prescription drug sales
Korean offshoots of Japanese pharmaceutical companies are worrying that the...
by Kim Yun-mi  |  2019-08-06 15:44
라인
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech
Roche, MSD (Merck in the U.S.), and AstraZeneca achieved the most significa...
by Kim Yun-mi  |  2019-08-06 11:29
라인
Amgen’s lipid-lowering Repatha beats Sanofi’s Praluent in Q2 sales
Amgen won the battle against Sanofi in sales of cholesterol-lowering PCSK9 ...
by Kim Yun-mi  |  2019-08-05 15:37
라인
‘MSD Korea playing tricks to maintain monitoring on salespersons’
MSD Korea’s labor and management are again in dispute over the so-called “s...
by Kim Yun-mi  |  2019-08-02 15:48
라인
Conflict erupts between employees of Takeda, Shire during merger
Takeda Pharmaceutical Korea’s labor union said Takeda employees faced unfai...
by Kim Yun-mi  |  2019-08-02 14:23
라인
‘Recurrent chronic lymphocytic leukemia needs various treatment options’
Chronic lymphocytic leukemia (CLL) progresses more slowly than acute blood ...
by Kim Yun-mi  |  2019-08-01 15:31
라인
Novartis fails to expand heart failure drug Entresto’s indication
Novartis said its phase-3 Paragon-HF trial on heart failure treatment Entre...
by Kim Yun-mi  |  2019-07-31 14:26
라인
‘FDA likely to OK 11 blockbuster candidates in August’
The U.S. Food and Drug Administration (FDA) will likely approve 11 innovati...
by Kim Yun-mi  |  2019-07-29 16:55
라인
Takeda’s Zejula poised to change local ovarian cancer treatment market
Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance be...
by Kim Yun-mi  |  2019-07-29 12:04
라인
Will Gilead enter the autoimmune diseases market?
Gilead Sciences is highly likely to buy Otezla (apremilast), a new oral PDE...
by Kim Yun-mi  |  2019-07-22 17:34
라인
Employees file suit against Galderma Korea
Galderma Korea has recently been sued by its labor union. The company’s lab...
by Kim Yun-mi  |  2019-07-19 15:41
라인
2 cancer immunotherapy makers face different situations in reimbursement talks
Bristol-Meyers Squibb (BMS) is reportedly having a hard time persuading its...
by Kim Yun-mi  |  2019-07-18 16:01
라인
Korean pulmonary arterial hypertension patients’ survival far lower than Japanese
The three-year survival rate of Korean patients with pulmonary arterial hyp...
by Kim Yun-mi  |  2019-07-15 16:48
라인
Humira permitted for nursing, pregnant patients
The local regulator allowed nursing and pregnant patients to use autoimmune...
by Kim Yun-mi  |  2019-07-11 16:41
라인
‘Patients with myeloproliferative neoplasm unaware of cause before diagnosis’
Most patients with a myeloproliferative neoplasm (MPN) were unaware of the ...
by Kim Yun-mi  |  2019-07-02 16:42
라인
BMS Korea files administrative suit to appeal Eliquis price cut
The price reduction of BMS Korea Pharmaceutical’s blood thinner Elidquis ha...
by Kim Yun-mi  |  2019-07-01 14:16
여백
여백
여백
Back to Top